earnings

Novo Nordisk's Pricing Pressures Aren't Going Away
Novo Nordisk's Pricing Pressures Aren't Going Away
Motley Fool
Novo Nordisk
earnings
drug pricing
Flag link:
Endologix shares plunge on Q2 earnings miss
Endologix shares plunge on Q2 earnings miss
Mass Device
Endologix
earnings
Flag link:
Endo shares soar on Street-beating Q2
Endo shares soar on Street-beating Q2
Drug Delivery Business News
Endo Pharmaceuticals
earnings
Flag link:
Becton, Dickinson Sees Synergies From Bard With More to Come
Becton, Dickinson Sees Synergies From Bard With More to Come
Motley Fool
devices
earnings
Becton Dickinson
CR Bard
Flag link:
Mylan lowers outlook after Q2 earnings, sales miss estimates
Mylan lowers outlook after Q2 earnings, sales miss estimates
Drug Delivery Business News
Mylan Labs
earnings
Flag link:
Novo Nordisk sees lower US prices next year; second-quarter profit in line with forecasts
Novo Nordisk sees lower US prices next year; second-quarter profit in line with forecasts
CNBC
Novo Nordisk
earnings
drug prices
Flag link:
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
Motley Fool
Biomarin
earnings
Flag link:
AnaptysBio Inc.'s Lead Candidate Gets New Priorities -- The Motley Fool
AnaptysBio Inc.'s Lead Candidate Gets New Priorities -- The Motley Fool
Motley Fool
AnaptysBio
earnings
peanut allergy
Flag link:
Intercept superstar: revenues exceeding estimates, solid plans and shares rise 10%
Intercept superstar: revenues exceeding estimates, solid plans and shares rise 10%
GoinPharma
Intercept Pharma
earnings
Flag link:
Oncolytics Biotech (ONCY) Posts Earnings Results, Misses Expectations By $0.25 EPS
Oncolytics Biotech (ONCY) Posts Earnings Results, Misses Expectations By $0.25 EPS
The Daily Political
earnings
Oncolytics
Flag link:
Can MannKind Corporation Avert Bankruptcy?
Can MannKind Corporation Avert Bankruptcy?
Motley Fool
MannKind
earnings
Afrezza
Flag link:
With no partner, MorphoSys drops MOR202 in myeloma
With no partner, MorphoSys drops MOR202 in myeloma
Biopharma Dive
MorphoSys
earnings
anti-CD3 antibody
MOR202
Flag link:
Teva stock drops 4.5% in spite of Q2 profit beat, revenue match
Teva stock drops 4.5% in spite of Q2 profit beat, revenue match
Marketwatch
Teva Pharmaceutical
earnings
Copaxone
Flag link:
Exact Sciences Misses Revenue Estimates by $1.8 Million -- But It Cost the Company a Lot More
Exact Sciences Misses Revenue Estimates by $1.8 Million -- But It Cost the Company a Lot More
Motley Fool
EXACT Sciences
earnings
Flag link:
NewLink cuts 30% of staff to continue indoximod development
NewLink cuts 30% of staff to continue indoximod development
Biopharma Dive
earnings
NewLink Genetics
layoffs
restructuring
indoximod
Flag link:
Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss
Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss
Yahoo/Zacks.com
Sanofi
earnings
Flag link:
Pfizer Slips After Q2 Earnings Beat as Currency Moves Trim 2018 Revenue Forecast
Pfizer Slips After Q2 Earnings Beat as Currency Moves Trim 2018 Revenue Forecast
TheStreet.com
Pfizer
earnings
Flag link:
A Look at Teva’s Earnings Estimates ahead of Q2 Results
A Look at Teva’s Earnings Estimates ahead of Q2 Results
Market Realist
Teva Pharmaceutical
earnings
Copaxone
Flag link:
Seattle Genetics: 2Q Earnings Snapshot
Seattle Genetics: 2Q Earnings Snapshot
San Francisco Chronicle, CA
Seattle Genetics
earnings
Flag link:
Vertex and Alexion Are Schooling Big Biotech
Vertex and Alexion Are Schooling Big Biotech
Washington Post, DC
earnings
Vertex Pharmaceuticals
Alexion
Flag link:

Pages